Comprehensive Assessment of Neurodegeneration and Dementia
NCT ID: NCT03402919
Last Updated: 2026-01-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1573 participants
OBSERVATIONAL
2016-06-30
2029-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pilot Study on the Feasibility of Using Smartphone Data as a Diagnostic Marker for Alzheimer's Disease.
NCT05709210
Predictors of Cognitive Decline in Normal Aging
NCT00094939
Cohort Study on Cognitive Decline in Elderly
NCT07093892
China Longitudinal Aging and Cognitive Impairment Study
NCT05468905
A Cohort of Outpatients From French Research Memory Centers in Order to Improve Knowledge on Alzheimer's Disease and Related Disorders
NCT01926249
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
All subjects involved in the study underwent rigorous evaluations at baseline, including clinical assessment, neuropsychological assessment, genomics and neuroimaging. Biological samples from blood, saliva, urine, fecal matter, buccal cells and cerebrospinal fluid were collected, stored, and analyzed.
Longitudinal follow-up determining if there has been any change in their diagnosis was carried out annually and longitudinal re-evaluation was carried out at two times: Time 2 and Time 3.
In Time 3, 400 participants across the non-dementia cohorts (Cognitively Unimpaired, Subjective Cognitive Impairment, Mild Cognitive Impairment, Mild Cognitive Impairment with a Vascular Component, Parkinson's Disease with no Cognitive Impairment, Parkinson's Disease with Mild Cognitive Impairment) with up to 12 years of education will be recruited.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Normal healthy elderly
participants with no subjective or objective cognitive deficits or decline.
No interventions assigned to this group
Subjective Cognitive Decline
Participants with a complaint of subjective cognitive impairment, but no objective evidence of such.
No interventions assigned to this group
Mild Cognitive Impairment (MCI)
Participants with objective evidence of cognitive impairment, but it does not impact on daily function.
No interventions assigned to this group
Vascular MCI
Participants meeting criteria of MCI who also show signs of cerebrovascular disease on imaging but have no history of stroke.
No interventions assigned to this group
Alzheimer's Disease
Participants with dementia of the Alzheimer's type according to the National Institute of Aging-Alzheimer's Association criteria
No interventions assigned to this group
Dementia of Mixed Etiology
Participants with dementia and evidence of more than one etiology.
No interventions assigned to this group
Lewy Body/Parkinson's spectrum
Participants with Parkinson's disease who show mild or moderate cognitive impairment and/or dementia.
No interventions assigned to this group
Frontotemporal dementia (FTD) spectrum
Participants with behavioral variant FTD, primary progressive aphasia, progressive supranuclear palsy, or corticobasal syndrome
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Written informed consent must be obtained and documented (from the patient or, where jurisdictions allow it, from a caregiver/family member)
* Sufficient proficiency in English or French to undertake self report and neuropsychological testing
* Geographic accessibility to the study site
* Must have a study partner who can participate as required in the protocol (provide corroborative information)
* Up to 12 years of education
* Fits into one of the following groups: Cognitively Unimpaired, Subjective Cognitive Impairment, Mild Cognitive Impairment, Vascular Mild Cognitive Impairment, Parkinson's Disease, Parkinson's Disease with Mild Cognitive Impairment
Exclusion Criteria
* Ongoing alcohol or drug abuse which in the opinion of the investigator may interfere with the subject's ability to comply with the study procedures
* Symptomatic stroke within the previous year
* Unable to undergo MRI scan due to medical contraindications or inability to tolerate the procedure
50 Years
90 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Canadian Institutes of Health Research (CIHR)
OTHER_GOV
Alzheimer Society of Canada
OTHER
Sanofi
INDUSTRY
New Brunswick Health Research Foundation
OTHER
Saskatchewan Health Research Foundation
OTHER
Michael Smith Foundation for Health Research
OTHER
Nova Scotia Health Research Foundation
OTHER_GOV
Eli Lilly and Company
INDUSTRY
Canadian Nurses Foundation (CNF)
OTHER
Ontario Brain Institute
OTHER
Pfizer
INDUSTRY
Canadian Consortium on Neurodegeneration in Aging
OTHER
McGill University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Howard Chertkow
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael Borrie, MD
Role: STUDY_DIRECTOR
Western University
Natalie Philips, PhD
Role: STUDY_DIRECTOR
Concordia University, Montreal
Jaspreet Bhangu, MB
Role: STUDY_DIRECTOR
Western University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Calgary
Calgary, Alberta, Canada
University of Alberta Hospital
Edmonton, Alberta, Canada
Djavad Mowafaghian Centre for Brain Health
Vancouver, British Columbia, Canada
Island Health
Victoria, British Columbia, Canada
Veteran's Memorial Building
Halifax, Nova Scotia, Canada
Hamilton General Hospital
Hamilton, Ontario, Canada
St. Joseph's Health Care London
London, Ontario, Canada
Gait and Brain Lab
London, Ontario, Canada
Bruyère Research Institute
Ottawa, Ontario, Canada
Kawartha Centre
Peterborough, Ontario, Canada
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
University Health Network Memory Clinic
Toronto, Ontario, Canada
Baycrest Clinical Unit
Toronto, Ontario, Canada
University of Waterloo
Waterloo, Ontario, Canada
Research Institute of the McGill University Health Centre
Montreal, Quebec, Canada
Jewish General Hospital/McGill Memory Clinic
Montreal, Quebec, Canada
Clinique de cognition Institut universitaire de gériatrie de Montréal
Montreal, Quebec, Canada
Hôpital Enfant-Jésus
Québec, Quebec, Canada
Centre de recherche sur le vieillissement CIUSSS de l'Estrie-CHUS
Sherbrooke, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Montero-Odasso M, Sarquis-Adamson Y, Kamkar N, Pieruccini-Faria F, Bray N, Cullen S, Mahon J, Titus J, Camicioli R, Borrie MJ, Bherer L, Speechley M. Dual-task gait speed assessments with an electronic walkway and a stopwatch in older adults. A reliability study. Exp Gerontol. 2020 Dec;142:111102. doi: 10.1016/j.exger.2020.111102. Epub 2020 Oct 2.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Document Type: Informed Consent Form: Study Participant Informed Consent Form
Document Type: Informed Consent Form: Study Partner Informed Consent Form
Related Links
Access external resources that provide additional context or updates about the study.
This is a direct link to the study's website.
CIHR COMPASS-ND Study
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CCNA 2015
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.